pemetrexed krka
krka d.d. - pemetrexed disodium - carcinoma, non-small-cell lung; mesothelioma - aġenti antineoplastiċi - plewrali malinna mesotheliomapemetrexed krka flimkien ma ' cisplatin huwa indikat għat-trattament tal-kimoterapija naïve pazjenti b'mesoteljoma plewrali malinna u li ma jistax jitneħħa. taċ-ċelluli mhux żgħar tal-pulmun cancerpemetrexed krka flimkien ma 'cisplatin huwa indikat għall-kura tal-ewwel linja ta' pazjenti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi. pemetrexed krka huwa indikat bħala monoterapija għall-kura ta 'manteniment ta lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta' ċelluli skwamużi fir-pazjenti li l-marda tagħhom ma jkunx hemm progress immedjatament wara ibbażat fuq il-platinu ' kimoterapija. pemetrexed krka huwa indikat bħala monoterapija għall-tieni linja ta 'trattament ta' pazjenti b'lokalment avvanzat jew metastatiku taċ-ċelluli mhux żgħar tal-pulmun il-kanċer l-oħra mill-aktar istoloġija ta ' ċelluli skwamużi.
semglee
viatris limited - insulina glargine - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sentejn u aktar.
lyumjev (previously liumjev)
eli lilly nederland b.v. - insulina lispro - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sena u aktar. trattament tad-dijabete mellitus fl-adulti.
insulin aspart sanofi
sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
gencebok
gennisium pharma - kaffeina citrate - apnea - psychoanaleptics, - it-trattament tal-primarja apnea tal-trabi tat-twelid qabel iż-żmien.
kirsty (previously kixelle)
biosimilar collaborations ireland limited - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
sogroya
novo nordisk a/s - somapacitan - tkabbir - ormoni u analogi pitwitarji u ipotalamiċi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - aġenti antineoplastiċi - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
truvelog mix 30
sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogi użati fid-dijabete - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - aġenti antineoplastiċi - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.